Bausch Health Companies Inc. Deferred Tax Assets, Equity Method Investments
Bausch Health Companies Inc. (BHC) had Deferred Tax Assets, Equity Method Investments of $925.00 million as of 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsEquityMethodInvestments · last filed 2017-11-07
- 2017-09-30: Deferred Tax Assets, Equity Method Investments $925.00M.
- 2017-03-31: Deferred Tax Assets, Equity Method Investments $1.54B.
| Period end | Deferred Tax Assets, Equity Method Investments |
|---|---|
| 2017-09-30 | $925.00M 10-Q · filed 2017-11-07 |
| 2017-03-31 | $1.54B 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |